PEG-Hemoglobin Trial Underway

August 1, 1996
Oncology NEWS International, Oncology NEWS International Vol 5 No 8, Volume 5, Issue 8

PISCATAWAY, NJ--Enzon, Inc. has begun a multidose, multicen-ter clinical trial of its hemoglobin-based oxygen carrier, PEG-hemoglobin, in cancer patients receiving radiation therapy. The agent was developed as a radiosensitizer to increase oxygenation of hypoxic tumors cells that may be resistant to irradiation. Patients will receive once-a-week infusions of PEG-hemoglobin followed by 5 days of radiation therapy, repeated weekly for 3 weeks.

PISCATAWAY, NJ--Enzon, Inc. has begun a multidose, multicen-terclinical trial of its hemoglobin-based oxygen carrier, PEG-hemoglobin,in cancer patients receiving radiation therapy. The agent wasdeveloped as a radiosensitizer to increase oxygenation of hypoxictumors cells that may be resistant to irradiation. Patients willreceive once-a-week infusions of PEG-hemoglobin followed by 5days of radiation therapy, repeated weekly for 3 weeks.